FindTrial
Sign In

Intranasal administration of oxytocin in PWS

Intranasal administration of oxytocin in children with Prader-Willi Syndrome. Effects on satiety and food intake, and social behaviour

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
NL-OMON
Registry ID
NL-OMON21542
Enrollment
28
Registered
2015-01-08
Start date
2015-01-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Genetically confirmed diagnosis of Prader-Willi syndrome

Interventions

Oxytocin intranasal spray

Sponsors

Dutch Growth Research Foundation Westzeedijk 106, 3016 AH Rotterdam Tel: 010-2251533 info@kindengroei.nl
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: - Genetically confirmed diagnosis of Prader-Willi syndrome - Age between 6 and 14 years - Currently on growth hormone treatment for at least 1 year - Increased interest in food and/or problems social behavior

Exclusion criteria

Exclusion criteria: - Severe psychiatric problems - Non cooperative behaviour - Allergic reactions or hypersensitivity for oxytocin - Serious illness - Cardiac abnormalities - Extremely low dietary intake of less than minimal required intake according to WHO - Medication to reduce weight (fat)

Design outcomes

Primary

MeasureTime frame
To evaluate the effects of intranasal oxytocin administration on appetite, satiety and food intake in children with PWS.—

Secondary

MeasureTime frame
To evaluate the effects of intranasal oxytocin administration on social behavior in children with PWS.—

Contacts

Public ContactR.J. Kuppens

Dutch Growth Research Foundation

info@kindengroei.nl010-2251533

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)